AUXL is down 10%+ and I am surprised BSTC isn't down much more. Xiaflex sales are below expectations again. I am just listening to the Auxilium call now and they are completely shaking up their Xiaflex effort from people to their sales/marketing strategy.
I had some concerns about BSTC ability to receive their royalties in full and in EU past 2016 so I put the company on the backburner (I sent the company an e-mail but wasn't close to investing to follow up with a call when I didn't get a reply).
I don't like paying for Testim (too competitive/weak IP) and still think the Peyronie trial design is a bit risky but other than that...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.